Results 61 to 70 of about 40,297 (296)

Basal ganglia cryptococcomas presenting as parkinsonism in an immunocompetent patient

open access: yesIDCases
Cryptococcal disease typically presents as meningitis in immunocompromised hosts, whereas basal ganglia cryptococcomas causing parkinsonism in immunocompetent patients are uncommon and easily overlooked.
Lorena Lucía Plazas Ruiz   +3 more
doaj   +1 more source

Understanding fatigue in progressive supranuclear palsy

open access: yesScientific Reports, 2021
Fatigue is a common and disabling non-motor symptom (NMS) of Parkinson’s disease (PD); however, it has been poorly understood in patients with progressive supranuclear palsy (PSP).
Jong Hyeon Ahn   +4 more
doaj   +1 more source

Dementia Incidence in Individuals With Parkinson's Disease in the Framingham Heart Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Limited information exists on incident dementia in individuals with Parkinson's disease (PD) in US community‐based samples. We examined cognitive statuses and PD diagnoses of 183 individuals in the Framingham Heart Study (FHS) to establish incident dementia, mortality rates, associations with sex, age at PD onset, and education level.
Joshi Dookhy   +11 more
wiley   +1 more source

Fahr disease in the differential diagnosis of secondary parkinsonism-a

open access: yesLiječnički vjesnik : glasilo Hrvatskoga liječničkog zbora, 2019
Connection with Fahr's disease and parkinsonism.
Franić, Ivana Karla   +2 more
openaire   +2 more sources

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi   +5 more
wiley   +1 more source

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy

open access: yesDrug Design, Development and Therapy, 2017
Ádám Annus,1 László Vécsei1,2 1Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, 2MTA-SZTE Neuroscience Research Group, Szeged, Hungary Abstract: Parkinson ...
Annus Á, Vécsei L
doaj  

Recurrent Hypothermia and Autonomic Dysfunction Secondary to Shapiro Syndrome

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT A 44‐year‐old man presented with recurrent hypothermia, diaphoresis and hypertension. Extensive investigation for infectious, inflammatory, metabolic and endocrine aetiologies was negative. MR scan of the brain demonstrated no lesions but revealed callosal dysgenesis, consistent with Shapiro syndrome.
Naveen Kumar   +3 more
wiley   +1 more source

Eye lens crystallin proteins inhibit the autocatalytic amyloid amplification nature of mature α-synuclein fibrils.

open access: yesPLoS ONE, 2020
Parkinson´s disease is characterized by the accumulation of proteinaceous aggregates in Lewy bodies and Lewy Neurites. The main component found in such aggregates is α-synuclein.
Ricardo Gaspar   +2 more
doaj   +1 more source

A Two‐Stage Questionnaire and Actigraphy Screening for iRBD in a Multicenter Retrospective Cohort

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Isolated rapid‐eye‐movement sleep behavior disorder is a prodromal marker of synucleinopathies. However, most cases remain undiagnosed due to the insufficient predictive value of questionnaires and limited access to confirmatory video‐polysomnography. We assessed a two‐stage screening strategy combining a brief questionnaire on rapid‐
Caleb A. Massimi   +17 more
wiley   +1 more source

Neurochemical Endpoints to Inform Early‐Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy